Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use
NCT ID: NCT07218549
Last Updated: 2025-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
50 participants
INTERVENTIONAL
2026-05-01
2029-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience
NCT06072170
Reducing Pain and Opioid Use With CBD
NCT05299944
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
NCT00214942
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01323790
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain
NCT00214955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Sequence A
Placebo: A single dose of placebo to match kratom (over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Placebo
Placebo: A single dose of placebo to match kratom (over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Treatment Sequence B
Active Control: A single 20 mg dose of oxycodone (1 X 20 mg tablet over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Oxycodone HCl
Active Control: A single 20 mg dose of oxycodone (1 X 20 mg tablet over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Treatment Sequence C
Active Control: A single 40 mg dose of oxycodone (2 X 20 mg tablets over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Oxycodone HCl
Active Control: A single 40 mg dose of oxycodone (2 X 20 mg tablets over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Treatment Sequence D
Kratom: A single 8 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Kratom 8
Kratom: A single 8 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Treatment Sequence E
Kratom: A single 12 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Kratom 12g
Kratom: A single 12 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Treatment Sequence F
Kratom: A single 16 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Kratom 16g
Kratom: A single 16 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo: A single dose of placebo to match kratom (over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Oxycodone HCl
Active Control: A single 20 mg dose of oxycodone (1 X 20 mg tablet over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Oxycodone HCl
Active Control: A single 40 mg dose of oxycodone (2 X 20 mg tablets over-encapsulated placebo in 32 opaque 00 capsules) will be administered orally.
Kratom 8
Kratom: A single 8 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Kratom 12g
Kratom: A single 12 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Kratom 16g
Kratom: A single 16 g dose of kratom (in 32 opaque 00 capsules) will be administered orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female subjects must have a negative serum pregnancy test at time of screening and negative urine pregnancy test upon admission. In addition, female subjects must meet one of the following conditions:
* Is a woman of non-childbearing potential defined as no menses for at least 12 months with status confirmed by FSH and estradiol levels at screening or surgically sterile at screening visit OR
* Is a woman of childbearing potential and using a contraceptive method that is highly effective, with a failure rate of \<1%, from Screening until 9 months after receiving the study medication. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the dose of study intervention.
3. Male subjects must agree to the following from Day 1 until 9 months after receiving the study medication:
• Not donate fresh unwashed semen
Plus, either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
* Use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
* Use a male condom when engaging in any activity that allows for passage of ejaculate to another person
4. Physically healthy, as determined by a clinical interview with a physician, laboratory tests (urinalysis, blood chemistry, 12-lead ECG), physical examination, and self-reported medical history.
5. No current or past diagnosis of severe mental illness, as determined by a clinical interview.
6. Clinical laboratory test results (CMP, CBC, etc.) must be within the normal reference range or with acceptable deviations that are judged to be not clinically significant by a study physician.
7. Have a history of self-reported recreational opioid use as defined by at least 10 times in the past year and at least once in the 12 weeks before screening.
8. Able and willing to give signed informed consent, reliable, and willing to make themselves available for the study's duration and follow study procedures.
9. Agree not to consume any recreational drugs during the study (THC is excluded).
10. Able to perform study procedures as determined by clinical judgment.
11. Able to meet eligibility requirements of the Qualification Phase (i.e., drug discrimination) and Naloxone Challenges.
Exclusion Criteria
2. Current or past diagnosis of opioid use disorder or other substance use disorder (SUD) within the past year, excluding THC and nicotine-containing products. With regard to marijuana/THC, an individual must be able to tolerate 48 hours of abstinence from marijuana/THC products.
3. History of opioid overdose.
4. Using medication or supplements that might interact with kratom or oxycodone as determined by self-report during intake interview.
5. Treatment with any investigational drug during the last 30 days.
6. Participants on parole or probation.
7. Currently pregnant or trying to conceive or currently lactating as determined by blood pregnancy testing at screening, urine pregnancy testing at admission, and self-reporting during interview and study visits.
8. Current or recent history of significant violent or suicidal behavior or suicidal/homicidal risk as determined by the C-SSRS.
9. Sensitivity, allergy, or contraindications/allergies to kratom, opioids, or similar compounds.
10. Use prescription or nonprescription drugs and dietary supplements within seven days or five half-lives (whichever is longer) that, in the opinion of the study clinician may interfere with the investigational product.
11. Positive urine drug screen (UDS) for substances of abuse at each admission in the Qualification and Treatment phases, excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS excluding THC at any admission or any visit, the investigator, at their discretion, may reschedule a repeat of UDS until the UDS is negative, excluding THC, before the participant is permitted to participate in any phase of the study.
12. Positive alcohol breathalyzer test at each admission in the Qualification and Treatment Phase.
13. History of sensitivity to heparin or heparin-induced thrombocytopenia.
14. Has not donated blood or plasma within the last six weeks.
15. Has a history of increased intracranial pressure or brain tumors.
16. Has gastrointestinal obstruction, including paralytic ileus.
17. Has a history of seizure disorders.
18. Has a chronic obstructive pulmonary disease or cor pulmonale.
19. Has a history of anemia or any other significant hematologic disorder.
20. Has a condition or abnormality that, in the opinion of the PI or Study Physician, would compromise the safety of the patient or the quality of the data.
21. Has a major surgery planned within the next 6 months.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor College of Medicine
OTHER
Christopher D. Verrico
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher D. Verrico
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher D Verrico, PhD Pharmacology
Role: PRINCIPAL_INVESTIGATOR
Baylor College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Michael E DeBakey VA Medical Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-56391
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.